Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study

A retrospective, registry-based analysis to assess the outcomes of metastatic renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed dermatologic adverse events was performed. Data on mRCC patients treated with sunitinib or sorafenib were obtained from the Czech Clinica...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2012-12, Vol.23 (12), p.3137-3143
Hauptverfasser:	Poprach, A., Pavlik, T., Melichar, B., Puzanov, I., Dusek, L., Bortlicek, Z., Vyzula, R., Abrahamova, J., Buchler, T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Dermatology Disease-Free Survival Exanthema - chemically induced Female Hand-Foot Syndrome Humans Indoles - adverse effects Indoles - therapeutic use Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Kidneys Male Medical sciences Middle Aged Neoplasm Metastasis Nephrology. Urinary tract diseases Niacinamide - adverse effects Niacinamide - analogs & derivatives Niacinamide - therapeutic use Pharmacology. Drug treatments Phenylurea Compounds - adverse effects Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrroles - adverse effects Pyrroles - therapeutic use rash Registries renal cell cancer Retrospective Studies Skin - drug effects Skin involvement in other diseases. Miscellaneous. General aspects Sorafenib Sunitinib survival Treatment Outcome Tumors of the urinary system Vascular disorders of the skin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!